| Detected | Trial | Change |
|---|---|---|
| 2026-08-15 | NCT07643623 Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or… |
Recruitment opened |
| 2026-07-24 | NCT07589205 Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid… |
Primary endpoint(s) modified |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07265284 | A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With… | Psoriasis | Recruiting |
| NCT07377643 | IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in… | HER2-positive Breast Cancer | Recruiting |
| NCT06945107 | A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an… | Plaque Psoriasis | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT07295509 | A Study of Picankibart in Patients With Active Psoriatic Arthritis | Psoriatic Arthritis | Recruiting |
| NCT07490262 | A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy… | Hepatocellular Carcinoma (HCC) | Recruiting |
| NCT07643623 | Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or… | Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | Recruiting |
| Phase 1 | |||
| NCT06963281 | Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors | Solid Tumors | Recruiting |
| NCT07589205 | Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid… | Solid Tumor | Recruiting |